UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 21, 2009
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
| Delaware | | 000-30975 | | 911789357 |
| (State of Incorporation) | | (Commission File Number) | | (IRS Employer Identification |
| Number) | | | | |
| | 12325 Emmet Street, Omaha, Nebraska | | 68164 | |
| | (Address of principal executive offices) | | (Zip Code) | |
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Director.
Frank Witney, a member of the Board of Directors of Transgenomic, Inc., has submitted his resignation from the Board effective May 20, 2009. Mr. Witney’s resignation is due to his new role as President and Chief Executive Officer of Dionex.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: May 21, 2009 | TRANSGENOMIC, INC. |
| | By: | /s/ Debra A. Schneider Debra A. Schneider Chief Financial Officer |
| | | |
